These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12518707)

  • 1. Multiple-pool cell lifespan model of hematologic effects of anticancer agents.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2002 Aug; 29(4):311-37. PubMed ID: 12518707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect-response model for the time course of leukopenia with anticancer drugs.
    Minami H; Sasaki Y; Saijo N; Ohtsu T; Fujii H; Igarashi T; Itoh K
    Clin Pharmacol Ther; 1998 Nov; 64(5):511-21. PubMed ID: 9834043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
    Friberg LE; Henningsson A; Maas H; Nguyen L; Karlsson MO
    J Clin Oncol; 2002 Dec; 20(24):4713-21. PubMed ID: 12488418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic model for chemotherapy-induced anemia in rats.
    Woo S; Krzyzanski W; Jusko WJ
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):123-33. PubMed ID: 17891399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
    Karlsson MO; Molnar V; Bergh J; Freijs A; Larsson R
    Clin Pharmacol Ther; 1998 Jan; 63(1):11-25. PubMed ID: 9465838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
    Hansson EK; Wallin JE; Lindman H; Sandström M; Karlsson MO; Friberg LE
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):839-48. PubMed ID: 19680655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel.
    Minami H; Sasaki Y; Watanabe T; Ogawa M
    Jpn J Cancer Res; 2001 Feb; 92(2):231-8. PubMed ID: 11223553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).
    Friberg LE; Brindley CJ; Karlsson MO; Devlin AJ
    Eur J Clin Pharmacol; 2000 Nov; 56(8):567-74. PubMed ID: 11151746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of myelotoxic effects of chemotherapy from early leukopenic response: application of a mathematical model for granulopoiesis.
    Blumenson LE; Bross ID
    J Surg Oncol; 1979; 11(2):171-6. PubMed ID: 439901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population model for the leukopenic effect of etoposide.
    Karlsson MO; Port RE; Ratain MJ; Sheiner LB
    Clin Pharmacol Ther; 1995 Mar; 57(3):325-34. PubMed ID: 7697950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population cell life span models for effects of drugs following indirect mechanisms of action.
    Perez-Ruixo JJ; Kimko HC; Chow AT; Piotrovsky V; Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):767-93. PubMed ID: 16328102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor senescence as a determinant of drug response in vivo.
    Roninson IB
    Drug Resist Updat; 2002 Oct; 5(5):204-8. PubMed ID: 12450785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
    Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
    Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].
    Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Nagumo H; Utada Y; Okabe T; Kimura K; Hirano A; Kajiwara T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):815-9. PubMed ID: 11432350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population analysis of myelosuppression profiles using routine clinical data after the ICE (ifosfamide/carboplatin/etoposide) regimen for malignant gliomas.
    Yano Y; Kodawara T; Hongo H; Yano I; Kishi Y; Takahashi J; Inui K
    J Pharm Sci; 2009 Nov; 98(11):4402-12. PubMed ID: 19593785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-survival curves of cis-platinum, melphalan, and velban in human granulocyte/macrophage progenitor cells.
    Umbach GE; Singletary SE; Tomasovic B; Spitzer G; Hug V; Drewinko B
    Int J Cell Cloning; 1984 Nov; 2(6):335-40. PubMed ID: 6542929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.
    Alexandre J; Nicco C; Chéreau C; Laurent A; Weill B; Goldwasser F; Batteux F
    J Natl Cancer Inst; 2006 Feb; 98(4):236-44. PubMed ID: 16478742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental chemotherapy and concepts related to the cell cycle.
    Tannock IF
    Int J Radiat Biol Relat Stud Phys Chem Med; 1986 Feb; 49(2):335-55. PubMed ID: 3510996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of ZL-004 on raising leukocyte count].
    Sun HY; Li CG; Xiao L; Wang GP; Liu QH
    Yao Xue Xue Bao; 2010 Jun; 45(6):797-800. PubMed ID: 20939193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.